YORK, England, Aug. 9, 2017 /PRNewswire/ -- York Instruments, Ltd. (subsidiary of Croton Healthcare, LLC, Coral Springs, Florida) has signed agreements to place magnetoencephalography (MEG) systems at three leading neuroscience research universities in the UK and Germany. The University of York and the University of Glasgow in the UK and Germany's University of Konstanz will partner closely with York Instruments to develop the ground-breaking technology, as well pursue potential new applications using the company's recently released MEG technology.
The agreement expands upon a development partnership started in 2015. By first incorporating MEGSCAN™ core control electronics, the universities' MEG researchers will achieve an improved signal to noise ratio through ground breaking low noise electronics. With the full MEGSCAN™ system, the universities will end their reliance on expensive liquid helium, a dwindling non-renewable resource, and have the capability to measure healthy and pathological brain signals with unprecedented sensitivity.
York Instruments' CEO Gordon Baltzer said, "We are very pleased to be able to invite the Universities of York, Glasgow and Konstanz to be part of our growing network of pioneering MEG research and clinical sites worldwide looking to radically improve the field of MEG."
Later this year, the universities will install the first stage of control electronics, which will allow for higher levels of functional brain imaging. In addition to offering unprecedented low levels of electronic noise interference, the systems have a higher level of reliability, lower power consumption and will be upgradable to future revisions.
About York Instruments Ltd.
York Instruments, Ltd is a UK-based company specializing in magnetic measurements and their healthcare applications. Using the very latest technologies and methodologies, York instruments, Ltd is focused on magnetoencephalography (MEG) and its ability to effectively assess neural networks. York Instruments' revolutionary MEG technology allows for earlier and improved diagnostic capability in relation to a variety of neurological diseases and conditions. Additional information is available at: www.york-instruments.com.
Contact: Tyler Lecceadone, SeyferthPR, email@example.com
SOURCE York Instruments Ltd.